+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gout Therapeutics Market by Drug Class, Therapy Line, Route of Administration, Disease Condition, Distribution Channel - Global Forecast 2026-2032- Product Image
Gout Therapeutics Market by Drug Class, Therapy Line, Route of Administration, Disease Condition, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Gout Therapeutics Market by Drug Class, Therapy Line, Route of Administration, Disease Condition, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904565
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gout Therapeutics Market is projected to reach USD 3.78 Billion in 2026. It is expected to continue growing at a CAGR of 12.13%, reaching USD 7.58 Billion by 2032.

Gout therapeutics address one of the most common forms of inflammatory arthritis, driven by monosodium urate crystal deposition following sustained hyperuricemia. The treatment landscape spans acute flare control with NSAIDs, colchicine, corticosteroids, and selected IL-1 inhibition, alongside long-term urate-lowering therapy with xanthine oxidase inhibitors, uricosurics, and biologic options for refractory or tophaceous disease.

Clinical practice has moved toward treat-to-target serum urate management, commonly below 6 mg/dL and below 5 mg/dL in selected severe cases, as reflected in major rheumatology guidelines. Demand is reinforced by aging populations, chronic kidney disease, obesity, hypertension, diabetes, diuretic use, and rising recognition that gout is a chronic, controllable disease rather than an episodic pain condition requiring only short-term relief.

Transformative Shifts in the Gout Therapeutics Landscape

The gout treatment landscape is shifting from flare-centered prescribing to long-term disease modification. Allopurinol remains the guideline-preferred first-line urate-lowering therapy for most patients, while febuxostat, probenecid, pegloticase, and anti-inflammatory prophylaxis are positioned according to renal function, cardiovascular risk, tophi burden, medication tolerance, and prior treatment response.

Transformative momentum is also coming from precision medicine, adherence programs, and evidence supporting immunomodulator co-therapy with pegloticase in uncontrolled gout to improve sustained urate-lowering response and reduce immunogenicity. Safety monitoring, HLA-B*58:01 testing in high-risk ancestry groups, renal-dose optimization, patient-reported outcome tracking, and real-world outcomes evidence are becoming central to clinical differentiation and payer confidence.

Cumulative Impact of Artificial Intelligence on Gout Care

Artificial intelligence is beginning to influence gout therapeutics through earlier detection, risk stratification, and more efficient care pathways. EHR-based models can flag patients with recurrent flares, elevated serum urate, chronic kidney disease, obesity, cardiovascular comorbidities, or diuretic exposure, enabling timely initiation, titration, and monitoring of urate-lowering therapy.

AI also supports imaging interpretation in ultrasound and dual-energy CT, clinical trial matching, pharmacovigilance signal detection, medication persistence monitoring, and patient adherence analytics. Its value depends on transparent validation, representative datasets, privacy safeguards, physician oversight, and alignment with established diagnostic and treatment standards to avoid bias and overdiagnosis.

Key Regional Insights Across Global Gout Therapeutics

Asia-Pacific is gaining strategic importance as China, India, Japan, South Korea, and Australia manage a rising gout burden linked to aging, urban diets, alcohol and purine-rich food exposure, renal disease, and metabolic syndrome. North America remains a mature gout therapeutics environment with high diagnosis rates, established rheumatology and primary care infrastructure, strong laboratory monitoring capacity, and broader uptake of advanced therapies for uncontrolled or tophaceous gout.

Latin America shows growing demand for gout treatment, but access remains uneven due to variation in specialist availability, diagnostic testing, reimbursement, and biologic therapy affordability. Europe benefits from guideline-led care, health technology assessment, structured reimbursement evaluation, and strong pharmacovigilance systems that support evidence-based prescribing. The Middle East faces elevated cardiometabolic risk, particularly in Gulf health systems with high diabetes, obesity, and chronic kidney disease prevalence, while Africa remains underdiagnosed, with gout therapeutics access shaped by affordability, laboratory capacity, essential medicine availability, and primary care awareness.

Key Group Insights for Gout Therapeutics Adoption

ASEAN markets show expanding need for affordable urate-lowering therapy as urbanization, dietary transition, diabetes, obesity, and kidney disease increase gout risk, although diagnosis, serum urate monitoring, and specialist access vary widely across health systems. The GCC is shaped by high cardiometabolic disease prevalence, including obesity, diabetes, hypertension, and chronic kidney disease, creating strong need for integrated metabolic, nephrology, cardiology, and rheumatology care pathways.

The European Union emphasizes evidence-based prescribing, reimbursement scrutiny, pharmacovigilance, and clinical guideline alignment, supporting structured use of both established urate-lowering medicines and selected advanced therapies. BRICS countries combine large patient populations with strong demand for generics, scalable primary care models, and improved diagnosis in underserved settings. G7 markets lead in innovation adoption, biologics access, real-world evidence generation, and digital health integration, while NATO member countries benefit from overlapping advanced health infrastructure, coordinated regulatory standards in many member states, and resilient pharmaceutical supply priorities.

Key Country Insights in Gout Therapeutics

The United States has one of the best-documented gout burdens, with NHANES analyses estimating prevalence near 3.9% of adults, supporting strong demand for treat-to-target care, specialty management of uncontrolled gout, and adherence-focused programs. Canada, the United Kingdom, Germany, France, Italy, and Spain rely on mature guideline frameworks, laboratory monitoring, and established reimbursement pathways, while Russia, Mexico, and Brazil show opportunities tied to broader diagnosis, primary care education, and access to affordable urate-lowering medicines.

China and India represent high-volume gout therapeutics settings shaped by population scale, diet transition, rising metabolic disease, renal disease, and expanding specialty care networks. Japan, South Korea, and Australia combine aging demographics with strong clinical awareness, pharmacovigilance, guideline adoption, and interest in personalized safety strategies such as HLA-B*58:01 risk assessment in populations with higher allele prevalence and greater risk of severe cutaneous adverse reactions to allopurinol.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize treat-to-target solutions that combine urate-lowering therapy, flare prophylaxis, patient education, serum urate monitoring, and adherence support. Evidence-based dose titration, renal and cardiovascular risk assessment, drug interaction review, and safety screening can improve outcomes while reducing avoidable flares, emergency visits, joint damage, and tophi progression.

Commercial and access strategies should align with local reimbursement realities, generic competition, formulary requirements, and specialist capacity. Leaders can strengthen differentiation through real-world evidence, AI-enabled patient identification, specialty pharmacy support for refractory gout, culturally relevant adherence tools, and partnerships across nephrology, cardiology, endocrinology, rheumatology, and primary care networks.

Research Methodology

This executive summary is built on a structured review of verified clinical, regulatory, epidemiological, and market-relevant sources, including rheumatology guidelines, approved drug labels, clinical trial publications, public health datasets, pharmacovigilance references, and peer-reviewed gout burden studies. Insights were triangulated across treatment class, patient pathway, disease severity, comorbidity burden, region, payer environment, and access conditions.

The methodology emphasizes data-backed interpretation rather than speculative forecasting. Findings were assessed for consistency with established evidence on hyperuricemia management, acute flare control, chronic urate lowering, tophaceous gout, safety monitoring, access barriers, adherence challenges, and emerging digital health applications in diagnosis, monitoring, and care coordination.

Conclusion

Gout therapeutics are entering a more disciplined era defined by chronic disease control, precision safety, adherence improvement, and targeted use of advanced therapies. The field remains anchored by proven urate-lowering medicines, but unmet need persists in uncontrolled gout, delayed diagnosis, undertreatment, recurrent flares, tophi, comorbidity complexity, and poor long-term medication persistence.

Organizations that combine scientific credibility, evidence generation, AI-enabled care support, safety-focused personalization, and region-specific access strategies will be best positioned to improve patient outcomes and build durable leadership in gout treatment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gout Therapeutics Market, by Drug Class
7.1. Anti-Inflammatory Agent
7.1.1. Colchicine
7.1.2. Corticosteroid
7.2. Uricase Agent
7.2.1. Pegloticase
7.2.2. Rasburicase
7.3. Uricosuric Agent
7.3.1. Benzbromarone
7.3.2. Lesinurad
7.3.3. Probenecid
7.4. Xanthine Oxidase Inhibitor
7.4.1. Allopurinol
7.4.2. Febuxostat
7.4.3. Topiroxostat
8. Gout Therapeutics Market, by Therapy Line
8.1. First Line
8.2. Second Line
8.3. Third Line
9. Gout Therapeutics Market, by Route Of Administration
9.1. Injectable
9.1.1. Intravenous
9.1.2. Subcutaneous
9.2. Oral
10. Gout Therapeutics Market, by Disease Condition
10.1. Acute Gout
10.2. Chronic Gout
11. Gout Therapeutics Market, by Distribution Channel
11.1. Hospital Pharmacy
11.1.1. Inpatient Pharmacy
11.1.2. Outpatient Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Asia-Pacific Gout Therapeutics Market
13. North America Gout Therapeutics Market
14. Latin America Gout Therapeutics Market
15. Europe Gout Therapeutics Market
16. Middle East Gout Therapeutics Market
17. Africa Gout Therapeutics Market
18. ASEAN Gout Therapeutics Market
19. GCC Gout Therapeutics Market
20. European Union Gout Therapeutics Market
21. BRICS Gout Therapeutics Market
22. G7 Gout Therapeutics Market
23. NATO Gout Therapeutics Market
24. United States Gout Therapeutics Market
25. Canada Gout Therapeutics Market
26. Mexico Gout Therapeutics Market
27. Brazil Gout Therapeutics Market
28. United Kingdom Gout Therapeutics Market
29. Germany Gout Therapeutics Market
30. France Gout Therapeutics Market
31. Russia Gout Therapeutics Market
32. Italy Gout Therapeutics Market
33. Spain Gout Therapeutics Market
34. China Gout Therapeutics Market
35. India Gout Therapeutics Market
36. Japan Gout Therapeutics Market
37. Australia Gout Therapeutics Market
38. South Korea Gout Therapeutics Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Amgen Inc.
40.2. Arthrosi Therapeutics, Ltd.
40.3. AstraZeneca plc
40.4. Cartesian Therapeutics
40.5. Cipla Limited
40.6. Dr. Reddy’s Laboratories Ltd.
40.7. GlaxoSmithKline plc
40.8. Horizon Therapeutics plc
40.9. Ironwood Pharmaceuticals, Inc.
40.10. Lupin Limited
40.11. Merck & Co., Inc.
40.12. Novartis AG
40.13. Olatec Therapeutics LLC
40.14. Pfizer Inc.
40.15. Protalix BioTherapeutics, Inc.
40.16. Sobi
40.17. Sun Pharmaceutical Industries Ltd.
40.18. Synlogic, Inc.
40.19. Takeda Pharmaceutical Company Limited
40.20. Teijin Pharma Limited
40.21. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL GOUT THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL GOUT THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL GOUT THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL GOUT THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GOUT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL GOUT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. GCC GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. GCC GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. G7 GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. G7 GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. NATO GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. NATO GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. CANADA GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. MEXICO GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. BRAZIL GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. GERMANY GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. FRANCE GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. RUSSIA GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. ITALY GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. SPAIN GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CHINA GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. INDIA GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. JAPAN GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. AUSTRALIA GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GOUT THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GOUT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL GOUT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTI-INFLAMMATORY AGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTI-INFLAMMATORY AGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTI-INFLAMMATORY AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL COLCHICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL COLCHICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL COLCHICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CORTICOSTEROID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CORTICOSTEROID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CORTICOSTEROID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL URICASE AGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL URICASE AGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL URICASE AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PEGLOTICASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PEGLOTICASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PEGLOTICASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL RASBURICASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL RASBURICASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL RASBURICASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL URICOSURIC AGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL URICOSURIC AGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL URICOSURIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BENZBROMARONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BENZBROMARONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BENZBROMARONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL LESINURAD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL LESINURAD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL LESINURAD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PROBENECID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PROBENECID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PROBENECID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL XANTHINE OXIDASE INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL XANTHINE OXIDASE INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL XANTHINE OXIDASE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ALLOPURINOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ALLOPURINOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ALLOPURINOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL FEBUXOSTAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL FEBUXOSTAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL FEBUXOSTAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL TOPIROXOSTAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL TOPIROXOSTAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL TOPIROXOSTAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL THIRD LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL THIRD LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL THIRD LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ACUTE GOUT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ACUTE GOUT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ACUTE GOUT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CHRONIC GOUT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CHRONIC GOUT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CHRONIC GOUT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL INPATIENT PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL INPATIENT PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL INPATIENT PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL OUTPATIENT PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL OUTPATIENT PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL OUTPATIENT PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 133. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 135. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 136. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 137. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 138. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 139. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 140. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 142. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 143. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 157. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 158. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 159. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 160. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 161. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 162. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 163. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 164. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 166. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 167. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 169. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 170. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 171. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 172. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 173. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 174. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 175. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 176. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 178. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 179. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 181. GCC GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 182. GCC GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 183. GCC GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 184. GCC GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 185. GCC GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 186. GCC GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 187. GCC GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 188. GCC GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 189. GCC GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 190. GCC GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 191. GCC GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. GCC GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 205. BRICS GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 206. BRICS GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 207. BRICS GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 208. BRICS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 209. BRICS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 210. BRICS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 211. BRICS GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 212. BRICS GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. BRICS GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 214. BRICS GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 215. BRICS GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. BRICS GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 217. G7 GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 218. G7 GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 219. G7 GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 220. G7 GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 221. G7 GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 222. G7 GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 223. G7 GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 224. G7 GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225. G7 GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 226. G7 GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 227. G7 GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. G7 GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 229. NATO GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 230. NATO GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 231. NATO GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 232. NATO GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 233. NATO GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 234. NATO GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 235. NATO GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 236. NATO GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. NATO GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 238. NATO GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 239. NATO GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. NATO GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 253. CANADA GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 254. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 255. CANADA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 256. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 257. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 258. CANADA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 259. CANADA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 260. CANADA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 261. CANADA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 262. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 263. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 264. CANADA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 265. MEXICO GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 266. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 267. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 268. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 269. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 270. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 271. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 272. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 273. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 274. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 275. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 276. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 277. BRAZIL GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 278. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 279. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 280. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 281. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 282. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 283. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 284. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 285. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 286. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 287. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 288. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 294. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 296. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 297. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 298. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 299. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 300. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 301. GERMANY GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 302. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 303. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 304. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 305. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 306. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 307. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 308. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 309. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 310. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 311. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 312. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 313. FRANCE GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 314. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 315. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 316. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 317. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 318. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 319. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 320. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 321. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 322. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 323. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 324. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 325. RUSSIA GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 326. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 327. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 328. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 329. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 330. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 331. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 332. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 333. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 334. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 335. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 336. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 337. ITALY GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 338. ITALY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 339. ITALY GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 340. ITALY GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 341. ITALY GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 342. ITALY GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 343. ITALY GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 344. ITALY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 345. ITALY GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 346. ITALY GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 347. ITALY GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 348. ITALY GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 349. SPAIN GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 350. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 351. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 352. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 353. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 354. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 355. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 356. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 357. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 358. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
TABLE 359. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 360. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 201

Companies Mentioned

The companies featured in this Gout Therapeutics market report include:
  • Amgen Inc.
  • Arthrosi Therapeutics, Ltd.
  • AstraZeneca plc
  • Cartesian Therapeutics
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • GlaxoSmithKline plc
  • Horizon Therapeutics plc
  • Ironwood Pharmaceuticals, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Olatec Therapeutics LLC
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Sobi
  • Sun Pharmaceutical Industries Ltd.
  • Synlogic, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.78 Billion
Forecasted Market Value ( USD ) by 2032 $ 7.58 Billion
Compound Annual Growth Rate12.1%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Gout Therapeutics Market Report 2026 - Product Image

Gout Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Gout Therapeutics - Global Strategic Business Report - Product Image

Gout Therapeutics - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
Global Chronic Gout Market: Focus on Drug Class, Disease Type, Distribution Channel, Country, and Region - Analysis and Forecast, 2026-2036 - Product Image

Global Chronic Gout Market: Focus on Drug Class, Disease Type, Distribution Channel, Country, and Region - Analysis and Forecast, 2026-2036

  • Report
  • Global
From
Gout Therapeutics Market - Forecast from 2026 to 2031 - Product Image

Gout Therapeutics Market - Forecast from 2026 to 2031

  • Report
  • 151 Pages
  • Global
From
Gout Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030 - Product Image

Gout Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

  • Report
  • 180 Pages
  • Global
From

About the Market

The Gout Drug market is a subset of the Immune Disorders Drugs market, which includes treatments for a variety of conditions related to the immune system. Gout drugs are used to reduce the inflammation and pain associated with gout, a type of arthritis caused by the buildup of uric acid in the joints. These drugs can be taken orally or injected directly into the affected joint. Commonly prescribed gout drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine. Gout drugs are typically prescribed by a doctor and are available in both generic and brand-name forms. The cost of these drugs can vary depending on the type of drug, the dosage, and the form in which it is taken. Some companies in the Gout Drug market include Pfizer, Merck, Novartis, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.